

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 November 2003 (27.11.2003)

PCT

(10) International Publication Number  
**WO 03/097814 A2**

(51) International Patent Classification<sup>7</sup>: **C12N**  
(21) International Application Number: PCT/US03/15991  
(22) International Filing Date: 15 May 2003 (15.05.2003)  
(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
60/381,322 16 May 2002 (16.05.2002) US

(74) Agents: CAROL, Larcher et al.; Leydig, Voit & Mayer, LTD, Two Prudential Plaza, suite 4900, 180 North Stetson, Chicago, IL 60601-6780 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).

(84) Designated States (*regional*): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and  
(75) Inventors/Applicants (*for US only*): BOYD, Michael R. [US/US]; 109 Austill Avenue, Mobile, AL 36608 (US); BOKESCH, Heidi R. [US/US]; 6782 Sunny Brook Drive, Frederick, MD 21702 (US); O'KEEFE, Barry R. [US/US]; 8110 Glendale Drive, Frederick, MD 21702 (US); McKEE, Tawnya C. [US/US]; 17500 Taunton Drive, Gaithersbury, MD 20877 (US).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: SCYTOVIRINS AND RELATED CONJUGATES, FUSION PROTEINS, NUCLEIC ACIDS, VECTORS, HOST CELLS, COMPOSITIONS, ANTIBODIES AND METHODS OF USING SCYTOVIRINS

(57) Abstract: An isolated or purified antiviral protein consisting essentially of the amino acid sequence of SEQ ID NO: 1, an amino acid sequence that is about 90% or more identical to SEQ ID NO: 1, an amino acid sequence that is about 90% or more homologous to SEQ ID NO: 1, or an antiviral fragment of any of the foregoing; a variant, fusion protein or conjugate thereof; a composition comprising (i) at least one of the foregoing and (ii) a carrier, excipient or adjuvant; an isolated or purified nucleic acid consisting essentially of a nucleotide sequence encoding the amino acid sequence of the aforementioned antiviral protein or antiviral fragment thereof, or a variant or fusion protein of either of the foregoing; an isolated cell comprising an above-described isolated or purified nucleic acid; a composition comprising (i) an above-described isolated or purified nucleic acid, and (ii) a carrier, excipient or adjuvant; a method of inhibiting a viral infection of a host comprising administering a viral infection-inhibiting amount of at least one of an above-described antiviral protein or an antiviral fragment thereof, a variant or fusion protein of either of the foregoing, an above-described nucleic acid, or an isolated cell comprising an above-described nucleic acid; a method of inhibiting a virus in a biological sample or in/on an inanimate object comprising contacting the biological sample or the inanimate object with a viral-inhibiting amount of at least one of an above-described antiviral protein or an antiviral fragment thereof, or a variant, fusion protein or conjugate of either of the foregoing, antibodies and composition thereof, and a method of inhibiting infection of a mammal with a virus comprising administering to the mammal an anti-scytovirin antibody in an amount sufficient to induce in the mammal an immune response to the virus.

WO 03/097814 A2